Chronic kidney disease monitoring in Australian general practice.


Journal

Australian journal of general practice
ISSN: 2208-7958
Titre abrégé: Aust J Gen Pract
Pays: Australia
ID NLM: 101718099

Informations de publication

Date de publication:
03 2019
Historique:
entrez: 1 7 2019
pubmed: 1 7 2019
medline: 12 5 2020
Statut: ppublish

Résumé

Kidney Health Australia recommends regular monitoring of patients with chronic kidney disease (CKD) to reduce progression and prevent complications such as cardiovascular disease. The objective of this study was to examine how practice aligns with the recommendations in Kidney Health Australia's CKD guidelines. Australian general practice data from the NPS MedicineWise MedicineInsight program (1 January 2013 - 1 June 2016) for 19,712 adults with laboratory evidence of stage 3 CKD were analysed. Complete monitoring in these individuals was defined as having at least one recorded assessment of blood pressure, urine albumin-to-creatinine ratio, estimated glomerular filtration rate and serum lipids over an 18-month period. Complete monitoring was performed for 25% of the cohort; 54.9% among patients with concomitant diabetes and 14.1% among patients without diabetes. Patients with diabetes, hypertension and a documented diagnosis of CKD were more likely to have complete monitoring. There is room for improvement in monitoring of patients with stage 3 CKD, particularly for albuminuria, which was monitored in fewer than 50% of these patients.

Sections du résumé

BACKGROUND AND OBJECTIVES
Kidney Health Australia recommends regular monitoring of patients with chronic kidney disease (CKD) to reduce progression and prevent complications such as cardiovascular disease. The objective of this study was to examine how practice aligns with the recommendations in Kidney Health Australia's CKD guidelines.
METHOD
Australian general practice data from the NPS MedicineWise MedicineInsight program (1 January 2013 - 1 June 2016) for 19,712 adults with laboratory evidence of stage 3 CKD were analysed. Complete monitoring in these individuals was defined as having at least one recorded assessment of blood pressure, urine albumin-to-creatinine ratio, estimated glomerular filtration rate and serum lipids over an 18-month period.
RESULTS
Complete monitoring was performed for 25% of the cohort; 54.9% among patients with concomitant diabetes and 14.1% among patients without diabetes. Patients with diabetes, hypertension and a documented diagnosis of CKD were more likely to have complete monitoring.
DISCUSSION
There is room for improvement in monitoring of patients with stage 3 CKD, particularly for albuminuria, which was monitored in fewer than 50% of these patients.

Identifiants

pubmed: 31256479
doi: 10.31128/AJGP-07-18-4630
doi:

Substances chimiques

Serum Albumin, Human ZIF514RVZR

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

132-137

Auteurs

Masuma A Khanam (MA)

MBBS, MPH, PhD, Post-doctoral Research Fellow, School of Health Sciences, University of Tasmania, Hobart, Tas.

Alex Kitsos (A)

BPhty(Hons), MMedStat, Health Analyst, College of Health and Medicine, University of Tasmania, Hobart, Tas.

Jim Stankovich (J)

PhD, Statistician, Monash University and Health Services Innovation Tasmania, School of Medicine, University of Tasmania, Hobart, Tas.

Leigh Kinsman (L)

BHlthSc, MHlthSc, PhD, Professor of Healthcare Improvement and Associate Head Research (Nursing), University of Tasmania, Tas.

Barbara Wimmer (B)

BPharm, MSc, PhD, Lecturer of Pharmacy, College of Health and Medicine, University of Tasmania, Hobart, Tas.

Ronald Castelino (R)

BPharm, MPharm, PhD, Lecturer in Pharmacy, University of Sydney and Adjunct Lecturer, University of Tasmania, Hobart, Tas.

Matthew Jose (M)

MBBS, FRACP, PhD, FASN, AFRACMA, Professor of Medicine, University of Tasmania; Consultant Nephrologist, Royal Hobart Hospital, Hobart, Tas.

Syed Tabish R Zaidi (STR)

BPharm, MPharm, PhD, Lecturer of Pharmacy, College of Health and Medicine, University of Tasmania, Hobart, Tas.

Jan Radford (J)

MBBS, FRACGP, MPsychMed, MEd, FARGP, Associate Professor of General Practice, Launceston Clinical School, University of Tasmania,@Launceston, Tas.

Gregory M Peterson (G)

BPharm, PhD, MBA, FSHP, FACP, GAICD, AACPA, ARPharmS, MPS, Professor of Pharmacy and Director of Health Services Innovation Tasmania, School of Medicine, University of Tasmania, Hobart, Tas.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH